Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ESPR

Esperion Therapeutics Inc.

Apr 15 • 04:00PM ET

1.93

Dollar change -0.21
Percentage change -9.58	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC JFWD AVUS QQQS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.11	Insider Own	1.10%	Shs Outstand	170.42M	Perf Week	-36.14%
Market Cap	329.76M	Forward P/E	36.77	EPS next Y	0.05	Insider Trans	0.00%	Shs Float	168.54M	Perf Month	-5.61%
Income	-209.25M	PEG	-	EPS next Q	0.05	Inst Own	48.11%	Short Float	11.82%	Perf Quarter	-35.93%
Sales	116.33M	P/S	2.83	EPS this Y	80.92%	Inst Trans	5.13%	Short Ratio	2.96	Perf Half Y	146.59%
Book/sh	-3.85	P/B	-	EPS next Y	113.58%	ROA	-92.23%	Short Interest	19.92M	Perf Year	43.33%
Cash/sh	0.48	P/C	4.01	EPS next 5Y	16.90%	ROE	-	52W Range	0.70 - 3.40	Perf YTD	-35.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.09%	ROI	-422.11%	52W High	-43.09%	Beta	0.86
Dividend TTM	-	Quick Ratio	0.87	Sales past 5Y	7.64%	Gross Margin	62.67%	52W Low	176.43%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	1.29	EPS Y/Y TTM	40.41%	Oper. Margin	-122.46%	RSI (14)	34.45	Volatility	13.76% 12.62%
Employees	240	Debt/Eq	-	Sales Y/Y TTM	54.14%	Profit Margin	-179.87%	Recom	1.75	Target Price	7.41
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	33.60%	Payout	-	Rel Volume	1.01	Prev Close	2.14
Sales Surprise	12.58%	EPS Surprise	-3.80%	Sales Q/Q	71.38%	Earnings	Feb 27 BMO	Avg Volume	6.74M	Price	1.93
SMA20	-24.62%	SMA50	-22.80%	SMA200	9.59%	Trades		Volume	6,809,030	Change	-9.58%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-01-23	Upgrade	Northland Capital	Under Perform → Market Perform
Jun-15-23	Upgrade	BofA Securities	Underperform → Buy	$1.25 → $4
Mar-16-23	Downgrade	Northland Capital	Market Perform → Under Perform	$1
Mar-16-23	Downgrade	BofA Securities	Neutral → Underperform	$8 → $1.50
Mar-07-23	Upgrade	Credit Suisse	Underperform → Neutral	$6.50 → $7
Feb-27-23	Resumed	BofA Securities	Neutral	$8
Feb-24-23	Upgrade	Jefferies	Hold → Buy	$12
Feb-03-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$9
Aug-03-22	Downgrade	Credit Suisse	Neutral → Underperform	$7 → $6
May-05-22	Upgrade	JP Morgan	Underweight → Neutral	$6
Mar-10-22	Initiated	H.C. Wainwright	Buy	$22
Oct-19-21	Downgrade	Credit Suisse	Outperform → Neutral	$28 → $11
Oct-14-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$17 → $11
May-05-21	Downgrade	Stifel	Buy → Hold	$37 → $20
Apr-26-21	Resumed	Credit Suisse	Outperform	$45
Mar-11-21	Initiated	Morgan Stanley	Equal-Weight	$30
Feb-12-21	Downgrade	Jefferies	Buy → Hold	$30
Feb-09-21	Downgrade	Goldman	Neutral → Sell	$44 → $24

Show Previous Ratings

Apr-07-24 02:45PM	Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity (GlobeNewswire)
Apr-01-24 08:00AM	Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 (GlobeNewswire)
Mar-28-24 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report? (Zacks)
Mar-26-24 08:00AM	Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-24 04:00PM	Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 (GlobeNewswire) +14.41%
06:26PM	Loading…
Mar-22-24 06:26PM	U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use (Business Wire) +8.53%
03:10PM	U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use (GlobeNewswire)
11:04AM	CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events (GlobeNewswire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-28-24 08:34AM	Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.38%
07:41AM	Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues (Zacks)
Feb-27-24 09:38PM	Q4 2023 Esperion Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +10.27%
07:53AM	Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023 (GuruFocus.com)
07:20AM	Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:25AM	Esperion Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Loading…
06:00AM	Esperion Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Feb-16-24 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-15-24 03:13AM	Should You Sell Esperion Therapeutics (ESPR)? (Insider Monkey)
Feb-13-24 10:00AM	Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27 (GlobeNewswire)
Feb-01-24 02:00PM	RFK, Esperion Therapeutics Announce 2024 Promotional Schedule (GlobeNewswire)
Jan-23-24 04:00PM	Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-19-24 08:50AM	Why Is Esperion Therapeutics (ESPR) Stock Down 24% Today? (InvestorPlace) -6.05%
Jan-18-24 09:15PM	Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock (GlobeNewswire) -16.34%
04:00PM	Esperion Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-03-24 07:00AM	Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation (GlobeNewswire) -21.23%
Dec-18-23 08:00AM	Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +15.93%
Dec-13-23 04:00PM	U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet (GlobeNewswire)
Dec-07-23 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report? (Zacks) +5.33%
10:30AM	Loading…
Nov-13-23 10:30AM	Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023 (GlobeNewswire)
Nov-11-23 11:00AM	Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 (GlobeNewswire)
Nov-09-23 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -10.79%
Nov-08-23 01:16PM	Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues (Zacks)
11:04AM	Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:19AM	Esperion Therapeutics Inc (ESPR) Reports 79% Y/Y Growth in Q3 Total Revenue (GuruFocus.com) +7.74%
07:15AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:06AM	Esperion Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-01-23 10:01AM	Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-31-23 08:00AM	Esperion to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-24-23 08:00AM	Esperion to Report Third Quarter 2023 Financial Results on November 7 (GlobeNewswire)
Sep-12-23 10:15AM	American College of Cardiology Program to Increase Cholesterol Screenings (GlobeNewswire)
Aug-31-23 11:31AM	Why Is Esperion Therapeutics (ESPR) Down 10.6% Since Last Earnings Report? (Zacks)
Aug-28-23 08:00AM	Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +14.49%
Aug-26-23 11:00AM	Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023 (GlobeNewswire)
Aug-11-23 08:00AM	Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023 (GlobeNewswire)
Aug-08-23 04:15PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-23 08:06AM	With 77% ownership, Esperion Therapeutics, Inc. (NASDAQ:ESPR) boasts of strong institutional backing (Simply Wall St.)
Aug-02-23 09:06AM	Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues (Zacks) +5.92%
Aug-01-23 07:15AM	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +7.64%
06:05AM	Esperion Therapeutics: Q2 Earnings Snapshot (AP Finance)
06:00AM	Esperion Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-24-23 08:00AM	Esperion to Participate in BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-18-23 08:00AM	Esperion to Report Second Quarter 2023 Financial Results on August 1 (GlobeNewswire) +5.37%
Jul-17-23 06:00AM	Esperion to Report Second Quarter 2023 Financial Results on August 1 (GlobeNewswire)
Jul-07-23 08:00AM	Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023 (GlobeNewswire)
Jun-28-23 08:00AM	Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet (GlobeNewswire)
Jun-24-23 02:30PM	Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions (GlobeNewswire)
Jun-15-23 02:30PM	Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023 (GlobeNewswire) +11.38%
06:27AM	Not Many Are Piling Into Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Yet As It Plummets 28% (Simply Wall St.)
Jun-08-23 11:30AM	Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report? (Zacks)
08:00AM	Esperion to Present New Key Science at the American Diabetes Associations 83rd Scientific Sessions 2023 (GlobeNewswire)
Jun-07-23 09:54AM	When Will Esperion Therapeutics, Inc. (NASDAQ:ESPR) Turn A Profit? (Simply Wall St.)
Jun-05-23 08:00AM	Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023 (GlobeNewswire)
Jun-01-23 08:00AM	Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet (GlobeNewswire)
May-25-23 04:30PM	Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders (GlobeNewswire) -5.70%
May-24-23 08:00AM	Esperion to Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-12-23 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-23 09:55AM	Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up (Zacks)
May-09-23 08:25AM	Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.19%
07:14AM	Esperion Therapeutics: Q1 Earnings Snapshot (AP Finance)
07:00AM	Esperion Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 08:30AM	Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9 (GlobeNewswire)
May-01-23 08:00AM	Esperion to Participate in JMP Securities Life Sciences Conference (GlobeNewswire) +7.58%
Apr-27-23 08:00AM	Esperion to Participate in Bank of America Securities 2023 Health Care Conference (GlobeNewswire)
Apr-25-23 10:01AM	Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:00AM	Esperion to Report First Quarter 2023 Financial Results May 9, 2023 (GlobeNewswire)
Apr-19-23 08:42AM	Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC (GlobeNewswire)
Apr-06-23 05:39PM	7 Very Undervalued Penny Stocks to Buy in April 2023 (InvestorPlace) +7.94%
Apr-03-23 08:00AM	Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference (GlobeNewswire)
Mar-23-23 11:30AM	Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound? (Zacks) +6.85%
Mar-22-23 04:15PM	Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Mar-20-23 08:00AM	Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Mar-18-23 08:52AM	Analysts Just Slashed Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) EPS Numbers (Simply Wall St.)
Mar-17-23 12:57PM	Esperion (ESPR) Plummets 54% Over Milestone Payment Row (Zacks) -14.84%
08:28AM	5 big analyst cuts: First Republic stock slashed on 'unprecedented uncertainty' \| Pro Recap (Investing.com)
Mar-16-23 08:21AM	Esperions stock tumbles after disclosing dispute about milestone payment (MarketWatch) -54.27%
Mar-10-23 11:05AM	Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why (Zacks) -5.19%
Mar-08-23 08:00AM	International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk (GlobeNewswire)
Mar-06-23 02:45PM	Alternatives to Popular Cholesterol-Lowering Drug Cut Heart-Attack Risk (The Wall Street Journal) -19.95%
01:36PM	2 Biotech Stocks Options Traders Are Watching (Schaeffer's Investment Research)
08:15AM	Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors (Benzinga)
07:45AM	China stocks slip after growth target released, as Ciena shares pop on earnings beat (MarketWatch)
07:01AM	Esperion Therapeutics stock slumps 22% premarket as data from study of cholesterol-lowering drug fail to impress investors (MarketWatch)
Mar-04-23 10:30AM	Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients (GlobeNewswire)
Feb-24-23 01:40PM	Esperion Launches New Scientific Website (GlobeNewswire) +6.35%
Feb-23-23 08:00AM	Esperion to Participate in the Cowen 43rd Annual Healthcare Conference (GlobeNewswire)
05:57AM	Need To Know: The Consensus Just Cut Its Esperion Therapeutics, Inc. (NASDAQ:ESPR) Estimates For 2023 (Simply Wall St.)
Feb-22-23 09:06AM	Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down (Zacks)

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Warren Eric	Chief Commercial Officer	Sep 20 '23	Sale	1.25	742	924	68,318	Sep 21 05:06 PM
Warren Eric	Chief Commercial Officer	Aug 18 '23	Sale	1.41	243	344	69,060	Aug 21 04:32 PM
Warren Eric	Chief Commercial Officer	Jul 19 '23	Sale	1.58	106	168	69,303	Jul 20 04:38 PM
Warren Eric	Chief Commercial Officer	Jun 21 '23	Sale	1.48	603	894	69,409	Jun 22 04:45 PM
Warren Eric	Chief Commercial Officer	May 17 '23	Sale	1.62	219	356	70,012	May 18 04:07 PM
CARROLL J MARTIN	Director	May 11 '23	Buy	1.57	23,091	36,285	36,500	May 11 04:11 PM
CARROLL J MARTIN	Director	May 10 '23	Buy	1.49	8,409	12,545	13,409	May 11 04:11 PM
ROCAMBOLI STEPHEN	Director	May 10 '23	Buy	1.50	8,111	12,126	8,111	May 11 04:10 PM
Koenig Sheldon L.	President and CEO	May 09 '23	Buy	1.26	20,000	25,192	312,816	May 10 04:12 PM
Looker Benjamin	General Counsel	Apr 19 '23	Sale	1.27	1,290	1,641	83,663	Apr 20 04:12 PM
Foody Joanne M.	Chief Medical Officer	Apr 19 '23	Sale	1.27	938	1,192	127,064	Apr 20 04:11 PM
Warren Eric	Chief Commercial Officer	Apr 19 '23	Sale	1.28	115	147	70,231	Apr 20 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ESPR

Esperion Therapeutics Inc.

Upgrade your FINVIZ experience